戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                           At second line, a total of 16 patients received a fluoropyr
2 of checkpoint inhibitors in the treatment of second-line advanced NSCLC.
3 lid also covers Nocardia well and could be a second line agent.
4 of sarcoidosis were less likely to require a second-line agent (4.3% vs. 16.2%, P = 0.011).
5 ed by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the nonc
6 nd 96.2%) and valganciclovir (23.1%) and the second-line agent was foscarnet (73.1% and 84.6%).
7 iclovir as first-line agent and foscarnet as second-line agent.
8 teral sensitivities, and then using these as second-line agents.
9                                         This second line also develops SCC indistinguishable from the
10 nt-to-treat population, 414 (69.9%) received second-line and 256 (43.2%) received third-line therapy.
11 w challenged by the use of rituximab both as second-line and as first-line therapy.
12 atic germ cell tumor (GCT) can be cured with second-line and even third-line regimens.
13 -$27 000, vs $28 000 and $25 000 for current second-line and first-line regimens.
14 ls on first-line treatment, and 29 trials on second-line and subsequent treatment.
15 es (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples.
16 pilepticus, rather than additional trials of second-line anti-epileptic drugs, to avoid neuronal inju
17 ing number of strains fail to respond to the second-line antibiotic azithromycin(3).
18                                              Second-line antiretroviral therapy (ART) based on ritona
19 ciency virus (HIV)-infected children failing second-line antiretroviral therapy (ART) have no access
20                              WHO-recommended second-line antiretroviral therapy (ART) of a pharmacolo
21                                          For second-line antiretroviral therapy, WHO recommends a boo
22 or ritonavir-boosted lopinavir plus NRTI for second-line antiretroviral therapy.
23  under the assumption of universal access to second-line antiretroviral therapy.
24  that reduces the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug
25 utations to predict resistance to first- and second-line antituberculosis drugs and validated our pre
26 ll or nearly all conventional first-line and second-line antituberculosis drugs.
27                Given the low potency of many second-line antituberculous drugs, we hypothesized that
28 d pelvic floor rehabilitation represented a "second line" approach.
29 constructed a cohort of patients switched to second-line ART (1 January 2003 through 31 December 2008
30  a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa.
31 2.6, 95% CI 2.5-2.8; p<0.0001) and switch to second-line ART (HR 5.2, 4.4-6.1; p<0.0001]) compared wi
32                 Overall, 67 (6%) switched to second-line ART and 54 (4%) died.
33            Overall, few patients switched to second-line ART and switching happened late in the absen
34 e drug levels were at higher risk of failing second-line ART and thus should be closely monitored.
35      Adaptive VL achieved an ICER <1x GDP if second-line ART and VL costs simultaneously decreased to
36 use mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using
37 5 eligible patients, 10,352 (3%) switched to second-line ART during 782 ,412 person-years of follow-u
38 onitoring of first-line ART and switching to second-line ART in sub-Saharan Africa.
39 the randomised open-label SECOND-LINE trial, second-line ART NtRTI selection was made by either genot
40                                              Second-line ART regimens were based on ritonavir-boosted
41  resistance and nonadherence on switching to second-line ART requires clarification.
42                       The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23),
43                                  Switches to second-line ART were reported scarcely.
44 nitiating protease inhibitor (PI)-containing second-line ART within the Program for HIV Prevention an
45 7 644 received first-line ART, 1476 received second-line ART, and 1810 received both.
46 he risk of virological failure and switch to second-line ART.
47 n retention, and no viral load monitoring or second-line ART.
48 luded if they received >180 days of PI-based second-line ART.
49 T and 101 weeks (IQR 51-178) for patients on second-line ART.
50 ct NRTI activity in protease inhibitor-based second-line ART.
51 s underscore the need for expanded access to second-line ART.
52 erminant of virological failure in people on second-line ART.
53 ment of >/=1000 copies per mL) and switch to second-line ART.
54 ghting the value of viral load monitoring of second-line ART.
55                 We assessed drug survival of second-line biologic therapies and estimated the risk of
56   Little is known about the drug survival of second-line biologic therapies for psoriasis in routine
57 pport clinical decision making when choosing second-line biologic therapy for patients with psoriasis
58  Area and Severity Index at switching to the second-line biologic therapy were predictors of overall
59 -based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this po
60 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w
61                                              Second-line chemotherapy for patients with oesophagogast
62                         We also analysed the second-line chemotherapy.
63 ide reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in
64 inhibitor plus raltegravir as an alternative second-line combination.
65                     Patient cohorts included second-line CP CML (n = 286), third-/fourth-line CP CML
66  biologic therapies and decreased over time; second-line discontinuation because of adverse events wa
67 ld benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.
68                                              Second-line dovitinib in FGFR2(mut) and FGFR2(non-mut) a
69  [81%]) and one-third had resistance to >/=1 second-line drug (24/73 tested).
70 re ineligible for the new regimen because of second-line drug resistance, we projected a change in in
71  to expand treatment access, and the role of second-line drug resistance.
72  to expand treatment access, and the role of second-line drug resistance.
73                                      For the second-line drug streptomycin (STR), overall concordance
74 on-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.
75  with susceptibility, for all first-line and second-line drugs for tuberculosis.
76 ority of phenotypic resistance to first- and second-line drugs in MDR and XDR-TB.
77 rst-line and interferon-alfa and busulfan as second-line drugs of choice.
78 nd optimal treatment, particularly for toxic second-line drugs such as D-cycloserine.
79  (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as wel
80 ST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients wi
81 hat required extended therapy and the use of second-line drugs.
82 erculosis using tailored regimens containing second-line drugs.
83  for first-line drugs and 32 days sooner for second-line drugs.
84 -tuberculosis patients, only 44.7% (596) had second-line DST for both fluoroquinolones and second-lin
85                            We quantified the second-line DST results time and proportion of patients
86  time from specimen collection to phenotypic second-line DST results.
87                               Median time to second-line DST was 53 days (range, 8-259).
88            Of the 252 patients with complete second-line DST, 101 (40.1%) potentially initiated a sub
89                                          The second line expresses APP(KM670/671NL)/PSEN1(Deltaexon9)
90                                      Data on second-line failure and development of protease inhibito
91 e III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the
92 mucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irino
93  weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concen
94 state cancer, with no more than two previous second-line hormonal therapies, and a castrate concentra
95 gen deprivation therapy, most men respond to second-line hormonal therapies.
96                                              Second-line hormonal therapy (eg, antiandrogens, CYP17 i
97                           This PCO addresses second-line hormonal therapy for chemotherapy-naive men
98   However, guidelines have neither addressed second-line hormonal therapy for nonmetastatic CRPC nor
99 fliximab and adalimumab can be considered as second-line immunomodulatory agents for the treatment of
100 5% required oral steroids and 13.8% required second-line immunosuppression.
101           Forty-five (61%) patients received second-line immunotherapy (cyclophosphamide, rituximab,
102 lgesic (49.1% of patients); opiates are the "second line" in 31.5% of patients; however, 33% patients
103                                            A second line included these 17 putative sites plus the fi
104 -for-age z score < -2 standard deviations at second-line initiation (aHR, 2.8; P = .03), and undetect
105 ctable drug levels within 6 months following second-line initiation (aHR, 4.5; P < .001).
106 nge [IQR], 1.4-3.3 years), and median age at second-line initiation was 10.7 years (IQR, 6.3-13.4 yea
107 he risk of treatment failure 24 months after second-line initiation was 41%.
108 h resistance to both a fluoroquinolone and a second-line injectable (XDR).
109  least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for a
110 ST results for at least fluoroquinolones and second-line injectable drugs, and not having extensively
111 oroquinolone-resistant multidrug resistance, second-line injectable-resistant multidrug resistance, a
112 econd-line DST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Wester
113 mycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Hea
114 lates resistant to fluoroquinolones (Fqs) or second-line injectables.
115 cond-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-base
116 ma, first-line PEM every 3 weeks followed by second-line IPI or first-line NIVO followed by second-li
117        Results PEM every 3 weeks followed by second-line IPI was both more effective and less costly
118                                              Second-line LA-ART and first-line LA-ART became cost-eff
119 for patients with multiple ART failures; (2) second-line LA-ART for those failing first-line therapy;
120 e analysis; 32% received T-DM1 as first- and second-line line therapy, and 48% received it as fourth-
121 nce supports alternatives to splenectomy for second-line management of patients with persistently low
122 ts remain excellent candidates for first and second-line medical therapies.
123   Epinephrine is life-saving in anaphylaxis; second-line medications (including antihistamines and gl
124  51 (74%) and 18 (26%) treated in first- and second-line metastatic settings, respectively.
125                                    Second, 6 second-line new agents have been recently developed and
126 s in patients with CRPC receiving first- and second-line NHT and, to the best of our knowledge, is th
127 ohort (and separately for the first-line and second-line NHT cohorts) were best for CTC- patients, in
128 1 through October 2015, 38 patients received second-line nintedanib plus docetaxel.
129  also separately examined the first-line and second-line novel hormonal therapy (NHT) settings.
130 culated the predicted activity of prescribed second-line NRTIs.
131 income settings for the purpose of selecting second-line NRTIs.
132 hods because of progression of disease after second-line OAC, particularly if vitreous seeds are pres
133 ay epithelial basal cells, which serves as a second line of airway epithelial defense that is induced
134      In addition, Tyr-92 was identified as a second line of defense to maintain the position of Phe-1
135  analyses of 37 orangutan genomes provided a second line of evidence.
136 llow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000
137 atment for tuberculosis, and preservation of second line options.
138 d rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in pati
139  following a complete or partial response to second-line or later platinum-based chemotherapy.
140 ol-defined population (patients who received second-line or later treatment); safety was also assesse
141 stigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with adv
142 this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overal
143 to investigate whether vorinostat given as a second-line or third-line therapy improved patients' ove
144 aemia in complete or partial remission after second-line or third-line treatment.
145 tries and randomly assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or place
146                                              Second-line oral treatments recommended include an opioi
147                           Safe, efficacious, second-line pharmacological treatment options exist for
148                       Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing A
149 It is important to identify risk factors for second-line regimen failure.
150 tor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-li
151 ad >400 copies/mL after at least 6 months on second-line regimen or death.
152   A total of 111 children started a PI-based second-line regimen, including 59 girls (53%).
153  promote adherence and timely switching to a second-line regimen.
154                                    Providing second-line regimens and shifting treatment providers to
155 nd middle-income countries increasingly need second-line regimens with boosted protease inhibitors.
156 motherapy in the neoadjuvant and adjuvant or second-line setting compared with more widely adopted re
157                                       In the second-line setting, recommendations include docetaxel,
158 ials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized tria
159 n the treatment of metastatic disease in the second-line setting.
160 val for erlotinib versus chemotherapy in the second-line setting.
161 ncer, there is no established therapy in the second-line setting.
162 m(2) days 1, 8, and 15 every 28 days) in the second-line setting.
163 s studied in urothelial carcinoma are in the second-line setting; new targets include CD105, polo-lik
164 emental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer tre
165 his high-risk disease in both first-line and second-line settings.
166  of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overal
167               Previous prognostic models for second-line systemic therapy in patients with metastatic
168 sed study, we analysed patients who received second-line targeted therapy for metastatic renal cell c
169             The IMDC prognostic model in the second-line targeted therapy setting has an improved pro
170   Median overall survival since the start of second-line targeted therapy was 12.5 months (95% CI 11.
171 2012, we included 1021 patients treated with second-line targeted therapy.
172 ents for overall survival since the start of second-line targeted therapy.
173                             Cabazitaxel is a second-line taxane chemotherapeutic agent that provides
174 n modest but consistent; however, gains from second-line therapies have been disappointing.
175 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who
176 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an
177 p alternative first-line regimens and better second-line therapies.
178  months, but patients are rarely switched to second-line therapies.
179        AR drug may be used as an alternative second line therapy for treating HER2 + BC.
180             Ninety-two patients (35%) needed second-line therapy after a median of 49 months.
181        Patients with AL amyloidosis who need second-line therapy after response to up-front treatment
182  by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients
183 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%.
184 s, VEGF receptors, PDGFR-beta, and c-KIT, as second-line therapy both in patients with FGFR2-mutated
185 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).
186 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.
187 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma
188  reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence
189           The drug also has been approved as second-line therapy for polycythemia vera (PV).
190                        Corticosteroids are a second-line therapy for those who do not respond, are in
191 wo hundred patients potentially eligible for second-line therapy had a PSS of 5.3 (4.6-7.1) months, w
192 tients with organ progression at the time of second-line therapy had inferior survival.
193 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients
194 observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom fi
195    Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont
196             Purpose The standard of care for second-line therapy in patients with advanced pancreatic
197 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic
198 ll be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020.
199 and/or when treatment was given as first- or second-line therapy in the metastatic setting.
200 .8% of all patients who received any sort of second-line therapy in the TMZ arm.
201 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop
202       Splenectomy is usually proposed when a second-line therapy is needed.
203 pean centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in
204 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria
205                 The median time from ASCT to second-line therapy was 24.3 months.
206                                              Second-line therapy was administered for a median durati
207 % CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A com
208 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57
209 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be
210 omisation was stratified by age, response to second-line therapy, and prognostic factors.
211                                           As second-line therapy, fulvestrant should be administered
212                                          For second-line therapy, gemcitabine plus NAB-paclitaxel sho
213                                           As second-line therapy, he received interferon alfa-2b (IFN
214          To be a viable option for first- or second-line therapy, however, its cost must approach tha
215  subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus c
216      When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologi
217 rved in 22% and 12% of patients who received second-line therapy, respectively.
218                                           As second-line therapy, splenectomy and Rituximab are both
219 examethasone independently prolonged time to second-line therapy.
220 ming virological failure before switching to second-line therapy.
221 d Drug Administration of PD-1 inhibitors for second-line therapy.
222 ent treatment with nilotinib or dasatinib as second-line therapy.
223 ear or less, and progressive disease despite second-line therapy.
224 failure of these drugs; there is no approved second-line therapy.
225 irst-line setting and anetumab ravtansine as second-line therapy.
226 ained efficacy in BRAF(V600E)-mutated ECD as second-line therapy.
227 mproved patient counseling and selection for second-line therapy.
228 was overall survival since the initiation of second-line therapy.
229  to evaluate the efficacy of CA as first- or second-line therapy.
230 ay influence clinician and patient choice of second-line therapy.
231 t-line therapy, or tramadol or duloxetine as second-line therapy.
232 cythaemia vera without splenomegaly who need second-line therapy.
233 ore effective than either alone and provides second line treatment for those with rhinitis poorly con
234 on (AF) has emerged as a widespread first or second line treatment option.
235 rognostic factor for treatment failure after second-line treatment (HR, 1.2 per 10 years; 95% CI, 1.2
236 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation
237 axane for first-line treatment and T-DM1 for second-line treatment are recommended.
238                                 Responses to second-line treatment are uncommon.
239 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus
240 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c
241 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.
242 tment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistanc
243 xel, and could be regarded as a new standard second-line treatment for patients with advanced gastric
244 versible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamou
245 rvival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic color
246 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea
247 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode
248 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.
249 nd efficacy of amrubicin versus topotecan as second-line treatment for SCLC.
250 1 phototherapy may be considered a potential second-line treatment for VLS.
251 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i
252 -receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP).
253                                    Regarding second-line treatment in patients who received first-lin
254 vatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal
255 ty of afatinib compared with methotrexate as second-line treatment in patients with recurrent or meta
256 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo
257 with steroid-refractory disease, response to second-line treatment is dismal.
258                Radiotherapy can be used as a second-line treatment modality.
259 rinotecan with or without bevacizumab in the second-line treatment of metastatic colorectal cancer.
260  added to systemic therapy in the first- and second-line treatment of patients with colorectal liver
261 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced
262 ucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.
263 have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers.
264 ocarcinoma have a poor prognosis and limited second-line treatment options.
265 in the post-implementation group initiated a second-line treatment regimen more rapidly than those in
266         We observed that splenectomy for ITP second-line treatment was more effective than Rituximab
267 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec
268                                              Second-line treatment with ramucirumab did not significa
269                                              Second-line treatment with rituximab leads to response r
270           Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received L
271 servation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pe
272            FFS was defined by the absence of second-line treatment, nonrelapse mortality, and recurre
273 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie
274 med RR-TB and those reported to have started second-line treatment.
275 6 Italian centers, were submitted to ECP for second-line treatment.
276 ternative that is often, but not always, the second-line treatment.
277 ontrolled, phase 3 studies of first-line and second-line treatment.
278 l cancer who may benefit from gefitinib as a second-line treatment.
279  order of hormonal therapies for CRPC beyond second-line treatment.
280 ll consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.
281 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On
282 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro
283  that ruxolitinib is not superior to current second-line treatments for ET.
284 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ
285 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity
286                                              Second-line treatments, including hypomethylating agents
287 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b
288 rding which patients will benefit from which second-line treatments.
289  is inadequately treated with first-line and second-line treatments.
290  outcome after ESA failure and the effect of second-line treatments.
291 n may help to improve patient management and second-line trial design.
292         As part of the randomised open-label SECOND-LINE trial, second-line ART NtRTI selection was m
293 As; and (3) effects on OS were much lower in second-line trials (median [interquartile range] respons
294                            Empiric first and second-line triple treatments have unacceptable eradicat
295 hole-genome sequencing, encode resistance to second-line tuberculosis drugs.
296                                              Second-line use of bevacizumab on progression is more ef
297  by another arm to compare first-line versus second-line use of bevacizumab on progression, performed
298                                              Second-line VF was frequent in this setting.
299 us (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural v
300           Here, we report and characterize a second line with improved sensitivity (N1IP::Cre(HI)) to

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top